



TFW 1653

Attorney Docket: 26477U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Art Unit: 1653

HOCHMAN

Examiner: Unknown

Application No: 10/519,090

Filed: December 23, 2004

Title: **METHOD FOR SCREENING MODULATORS OF THE IMMUNE SYSTEM**

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:


- 1) Information Disclosure Statement;
- 2) PTO Form-1449 with 12 cited references;
- 3) Copy of International Search Report issued for PCT/IL03/00536;
- 4) Copies of 11 of the 12 cited references.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

Date: November 23, 2005

By:


Gary M. Math
Reg. No. 26,965
Gregory B. Kang
Reg. No. 45,273
Customer No. 20529

NATH & ASSOCIATES PLLC
1030 15th St., N.W., 6th Fl.,
Washington, D.C. 20005-1503
GMN/GBK/le (IDS)



Attorney Docket: 26477U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Art Unit: 1653

HOCHMAN

Examiner: Unknown

Application No: 10/519,090

Filed: December 23, 2004

Title: **METHOD FOR SCREENING MODULATORS OF THE IMMUNE SYSTEM**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

[XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

[] ii. a check in the amount required by 37 C.F.R. 1.17(p).

[] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

[] Certification report(e) below; and

[] a check in the amount as required by 1.17(p).

[] d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or

[XXX] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

Date: November 23, 2005

By: 

Gary M. Nath
Reg. No. 26,965
Gregory B. Kang
Reg. No. 45,273
Customer No. 20529

NATH & ASSOCIATES PLLC
1030 15th St., N.W., 6th Fl.,
Washington, D.C. 20005-1503
GMN/GBK/le (IDS.Statement)

FORM PTO-1449 INFORMATION DISCLOSURE CITATION		In re Application of: HOCHMAN		Art Unit: 1653
		Application No: 10/519,090	Filed: December 23, 2004	Examiner: Unknown

U.S. PATENT DOCUMENTS				
Examiner Initial	Document Number	Issue / Publication Date	Inventor	Filed
A1	5,849,990 A	15 Dec. 1998	Hochman	19 Dec. 1994

FOREIGN PATENT DOCUMENTS				
	Document Number	Publication Date	Country	Translation
A2				

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)	
A3	Assaf, N., et al., "An experimental model for infiltration of malignant lymphoma to the eye and brain", <u>Virchows Arch</u> , vol. 431, pages 459-467, (1997).
A4	XP-001155071: Hochman, J., et al., "Entry Routes of Malignant Lymphoma into the Brain and Eyes in a Mouse Model", <u>Cancer Research</u> , vol. 61, pages 5242-5247, (2001).
A5	XP-001155072: Hochman, J., et al., "#5506 Transfer of immunity towards lymphoma from mother to offspring in a mouse model", <u>Cancer Research</u> , vol. 43, page 1111, (2002).
A6	Hochman, J., et al., "#533 Enhanced intraocular infiltration of mouse lymphoma cells transduced with with human MDR1 cDNA", <u>Proceedings of the American Association for Cancer Research</u> , vol. 37, (1996).
A7	Hochman, J., et al., "Substrate-adhering lymphoid cells show impaired tumorigenicity and increased immunogenicity", <u>Nature</u> , vol. 290, pages 248-249, (1981).
A8	Hochman, J., et al., "Cell Adhesiveness Is Related to Tumorigenicity in Malignant Lymphoid Cells", <u>The Journal of Cell Biology</u> , vol. 99, pages 1282-1288, (1984).
A9	Galski, H., et al., "KT-5720 Reverses Multidrug Resistance in Variant S49 Mouse Lymphoma Cells Transduced With the Human MDR1 cDNA and in Human Multidrug-resistant Carcinoma Cells", <u>European Journal of Cancer</u> , vol. 31A, no. 3, pages 380-388, (1995).
A10	XP-009017994: Squartini, F., et al., "Transmission and Expression of the Leukemia Inducing Agent in BALB/cf(RIII) Mice", <u>Bibliotheca Haematologica</u> , vol. 39, pages 345-356, (1973).
A11	XP-009017999: Thuvander, A., et al., "Influence of Perinatal Ochratoxin A Exposure on the Immune System in Mice", <u>Natural Toxins</u> , vol. 4, pages 174-180, (1996).
A12	XP-001155073: Coste, A., et al., "Nasal Immunization of Mice with Virus-Like Particles Protects Offspring against Rotavirus Diarrhea", <u>Journal of Virology</u> , vol. 74, no. 19, pages 8966-8971, (2000).
A13	XP-001155074: Diwan, B.A., et al., "Multiorgan Transplacental and Neonatal Carcinogenicity of 3'-Azido-3'-deoxythymidine in Mice", <u>Toxicology and Applied Pharmacology</u> , vol. 161, pages 82-99, (1999).

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.